Mr McKiddie, a chartered accountant, will work in tandem with Shaolei McKie, senior investment manager, to orchestrate analysis, fundraising support and exit strategies for Archangels’ portfolio of Scottish life sciences and technology firms.

Operating for over 30 years, Archangels’ investor members have invested over £160 million in the most innovative early-stage companies, with disruptive technology, protectable IP and the potential to scale globally. The syndicate primarily invests alongside co-investment partners such as Scottish Enterprise and British Business Investments.

Mr McKiddie brings valuable expertise from his background in mechanical engineering and accounting. After graduating from Glasgow University, he spent eight years at PwC, starting his career in financial audit and later joining their transaction services team. In this role, he executed financial due diligence across a spectrum of sectors. His most recent role was as investment manager at Inverleith LLP.

Archangels have marked a series of notable exits in recent years, including the sale of Blackford Analysis, a medical AI business, to Bayer Pharma, and the sale of Optoscribe, an optical platform firm, to Intel in 2022.

Mr Ovens, joint MD at Archangels, said: “The recruitment of Dan gives us the additional capacity we need within the team to thoroughly assess quality deal-flow, whilst supporting and realising value within the existing portfolio.

“His engineering and accounting background provides an ideal skillset as we continue to invest in Scotland’s most exciting technology and life sciences businesses.”

Mr McKiddie added: “It’s an exciting time to join Archangels as its patient capital approach to supporting Scottish life sciences and technology businesses is more crucial than ever.

“Scotland has the potential to be a world-leading hub for those sectors and I’m looking forward to working with the team, the portfolio businesses and the membership to support that ambition.”